Advertisement
BIO or DHR or MTD
Which Stock Would AI Choose? Bio-Rad Laboratories (BIO) vs. Danaher (DHR) vs. Mettler-Toledo (MTD) Stock Comparison
Key Takeaways
- BIO, DHR, and MTD operate in overlapping life sciences and diagnostics markets, with varying scales and growth profiles.
- Recent market activity shows DHR posting stronger year-to-date returns compared to BIO and MTD, amid sector-wide pressures in academic and biopharma end markets.
- MTD delivered solid Q1 2026 sales growth and raised full-year guidance, reflecting resilience in precision instruments.
- BIO reported modest reported sales gains in Q1 2026 but faced currency-neutral declines, highlighting exposure to challenging academic segments.
- DHR maintains a larger market capitalization and diversified segments, with upcoming Q2 earnings expected to provide further clarity on diagnostics trends.
- Relative performance underscores trade-offs between stability in larger peers and potential volatility in smaller, specialized players.
Introduction
Investors and traders focused on the life sciences and diagnostics sector often evaluate BIO, DHR, and MTD together due to their shared exposure to research tools, clinical diagnostics, and precision measurement technologies. This comparison highlights differences in business scale, recent operational results, and market positioning within a competitive healthcare subsector. Professionals seeking diversified exposure or relative value opportunities, as well as those monitoring sector sentiment shifts, may find this analysis relevant for assessing how these stocks have navigated recent market conditions.
BIO Overview and Recent Performance
BIO (Bio-Rad Laboratories) develops and markets products for life science research and clinical diagnostics markets. In recent weeks, the stock has traded in a range influenced by Q1 2026 results showing reported net sales of $592.1 million, up 1.1% year-over-year, though currency-neutral sales declined 4.2%. Operating income improved, but net results reflected one-time items. Market sentiment has reflected ongoing challenges in academic end markets and broader biopharma dynamics, contributing to relatively flat year-to-date performance amid sector headwinds.
DHR Overview and Recent Performance
DHR (Danaher) operates across biotechnology, life sciences, and diagnostics segments, serving biopharma and clinical customers globally. Recent market activity shows the stock benefiting from its diversified portfolio, with year-to-date returns outpacing broader market benchmarks in some periods. The company is scheduled to report Q2 2026 earnings shortly, with analysts anticipating modest revenue growth. Sentiment has been shaped by acquisition activity in diagnostics and steady demand in core areas, supporting a more stable price trajectory compared to smaller peers.
MTD Overview and Recent Performance
MTD (Mettler-Toledo International) provides precision instruments and analytical solutions for laboratory and industrial applications. In recent market activity, the company reported Q1 2026 sales growth of 7% to $947.1 million and raised full-year adjusted earnings guidance, citing strength across regions. Stock performance has reflected these operational updates alongside broader sector trends, with year-to-date gains supported by consistent execution in high-margin product lines. Sentiment remains tied to industrial and research spending patterns.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots optimized for prevailing market conditions. While Tickeron offers hundreds of AI Trading Bots that trade thousands of different tickers, only the highest-performing and most suitable ones for current environments earn placement in this section. Available bots feature varied trading styles, strategies, timeframes, and performance statistics, with historical win rates and returns often ranging across different risk profiles. This resource allows traders to explore data-driven approaches tailored to individual preferences. Explore the full selection on the Trending AI Robots page.
Head-to-Head Comparison
Business models differ in scope: DHR offers the broadest diversification across multiple segments, while BIO focuses more narrowly on research and diagnostics tools, and MTD emphasizes precision measurement equipment. Growth drivers include biopharma R&D spending for all three, though MTD has shown stronger recent sales momentum. Recent momentum favors DHR on a year-to-date basis, with BIO lagging amid end-market softness. Risk factors encompass currency fluctuations and academic budget constraints for BIO, integration and cost pressures for DHR, and cyclical industrial demand for MTD. Sector exposure remains concentrated in healthcare tools, with valuation sensitivity varying by market capitalization—larger entities like DHR often exhibit lower beta. Market sentiment reflects cautious optimism tied to earnings visibility across the group.
Tickeron AI Verdict
Based on observable factors such as trend consistency in recent quarters, earnings stability, and relative positioning within the sector, Tickeron’s AI would likely assign a higher probability of near-term favorability to DHR due to its scale, diversified revenue streams, and steadier performance metrics amid mixed industry conditions. MTD presents competitive attributes through guidance raises, while BIO shows more variability. This assessment remains probabilistic and subject to evolving data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 2 FA rating(s) are green whileDHR’s FA Score has 1 green FA rating(s), and MTD’s FA Score reflects 1 green FA rating(s).
- BIO’s FA Score: 2 green, 3 red.
- DHR’s FA Score: 1 green, 4 red.
- MTD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 5 TA indicator(s) are bullish while DHR’s TA Score has 4 bullish TA indicator(s), and MTD’s TA Score reflects 5 bullish TA indicator(s).
- BIO’s TA Score: 5 bullish, 4 bearish.
- DHR’s TA Score: 4 bullish, 5 bearish.
- MTD’s TA Score: 5 bullish, 5 bearish.
Price Growth
BIO (@Medical/Nursing Services) experienced а +3.32% price change this week, while DHR (@Medical Specialties) price change was -6.05% , and MTD (@Medical Specialties) price fluctuated +1.31% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -5.78%. For the same industry, the average monthly price growth was -7.49%, and the average quarterly price growth was -21.89%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.55%. For the same industry, the average monthly price growth was +2.80%, and the average quarterly price growth was +1.12%.
Reported Earning Dates
BIO is expected to report earnings on Jul 30, 2026.
DHR is expected to report earnings on Oct 27, 2026.
MTD is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Medical/Nursing Services (-5.78% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-1.55% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BIO | DHR | MTD | |
| Capitalization | 8.39B | 135B | 26.8B |
| EBITDA | 440M | 7.08B | 1.25B |
| Gain YTD | 3.786 | -15.994 | -4.806 |
| P/E Ratio | 52.32 | 34.14 | 31.18 |
| Revenue | 2.59B | 24.8B | 4.09B |
| Total Cash | 1.57B | N/A | 60.6M |
| Total Debt | 1.38B | 18.5B | 2.23B |
BIO | DHR | MTD | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 17 | 18 | 46 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 6 Undervalued | 99 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 100 | |
SMR RATING 1..100 | 90 | 80 | 2 | |
PRICE GROWTH RATING 1..100 | 20 | 56 | 48 | |
P/E GROWTH RATING 1..100 | 11 | 72 | 51 | |
SEASONALITY SCORE 1..100 | 85 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (6) in the Medical Specialties industry is significantly better than the same rating for BIO (85) and is significantly better than the same rating for MTD (99). This means that DHR's stock grew significantly faster than BIO’s and significantly faster than MTD’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BIO (100) and is in the same range as MTD (100). This means that DHR's stock grew similarly to BIO’s and similarly to MTD’s over the last 12 months.
MTD's SMR Rating (2) in the Medical Specialties industry is significantly better than the same rating for DHR (80) and is significantly better than the same rating for BIO (90). This means that MTD's stock grew significantly faster than DHR’s and significantly faster than BIO’s over the last 12 months.
BIO's Price Growth Rating (20) in the Medical Specialties industry is in the same range as MTD (48) and is somewhat better than the same rating for DHR (56). This means that BIO's stock grew similarly to MTD’s and somewhat faster than DHR’s over the last 12 months.
BIO's P/E Growth Rating (11) in the Medical Specialties industry is somewhat better than the same rating for MTD (51) and is somewhat better than the same rating for DHR (72). This means that BIO's stock grew somewhat faster than MTD’s and somewhat faster than DHR’s over the last 12 months.
| BIO | DHR | MTD | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 68% | 3 days ago 46% | 3 days ago 67% |
| Stochastic ODDS (%) | 3 days ago 69% | 3 days ago 61% | 3 days ago 65% |
| Momentum ODDS (%) | 3 days ago 71% | 3 days ago 65% | 3 days ago 66% |
| MACD ODDS (%) | 3 days ago 67% | 3 days ago 70% | 3 days ago 67% |
| TrendWeek ODDS (%) | 3 days ago 65% | 3 days ago 64% | 3 days ago 61% |
| TrendMonth ODDS (%) | 3 days ago 66% | 3 days ago 53% | 3 days ago 58% |
| Advances ODDS (%) | 4 days ago 65% | 4 days ago 54% | 11 days ago 60% |
| Declines ODDS (%) | 6 days ago 69% | 6 days ago 61% | 7 days ago 66% |
| BollingerBands ODDS (%) | 3 days ago 90% | 3 days ago 57% | 3 days ago 86% |
| Aroon ODDS (%) | 3 days ago 59% | 3 days ago 54% | 3 days ago 53% |
Advertisement
BIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | -0.52% | ||
| TMO - DHR | 77% Closely correlated | -0.71% | ||
| A - DHR | 73% Closely correlated | -0.84% | ||
| RGEN - DHR | 68% Closely correlated | -4.10% | ||
| BIO - DHR | 64% Loosely correlated | -0.61% | ||
| BRKR - DHR | 58% Loosely correlated | -2.74% | ||
More | ||||